Abstract: Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia. Idiopathic pulmonary fibrosis is often seen in elderly men who smoke. A diagnosis of IPF is based on a combination of a detailed clinical history, specific physical examination, laboratory findings, pulmonary function tests, high-resolution computed tomography (HRCT) of the chest, and histopathology. Idiopathic pulmonary fibrosis has a heterogeneous clinical course, from an asymptomatic stable state to progressive respiratory failure or acute exacerbation (AE). Acute exacerbation of IPF has several important differential diagnoses, such as heart failure and volume overload. The International Working Group project proposed new criteria for defining AE of IPF in 2016, which divides it into triggered and idiopathic AE. On the basis of these criteria, physicians can detect AE of IPF more easily. The recent international IPF guidelines emphasized the utility of chest HRCT. In addition, two antifibrotic agents have become available. We should focus on both the management and prevention of AE. The diagnostic process, laboratory findings, typical chest imaging, management, and prognosis of AE are comprehensively reviewed in this article.

Keywords: acute exacerbation; consolidation; GGO; HRCT; idiopathic; IPF; LDH; nintedanib; pirfenidone; triggered

1. Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic parenchymal lung disease with unknown etiology and is the most common fibrotic lung disease of all idiopathic interstitial pneumonias [1]. The majority of IPF patients are male, greater than 60 years old, and smokers [1,2]. Familial clustering is identified in approximately 3% of cases [3]. Genetic factors, such as MUC5B, are associated with the development of IPF [4,5]. The natural history of IPF is quite heterogeneous, from chronic stable symptoms to progressive respiratory failure or acute exacerbation (AE) [6]. The incidence of AE of IPF is 5–10% per year [7]. However, the incidence varies according to ethnicity. Japanese patients are more susceptible to AE of IPF [8]. Therefore, some genetic regulatory factors may be related to AE [9]. In addition, after the introduction of antifibrotic agents, the incidence of AE may be decreased. In this review, I will describe clinical pictures, laboratory findings, and chest imaging, especially high-resolution computed tomography (HRCT) findings, as well as the management and prognosis of AE of IPF.

2. Risk Factors

Studies have reported that reduced pulmonary function, especially forced vital capacity (FVC), never smoking status, and baseline serum Krebs von den Lungen-6 (KL-6) are crucial risk factors that predict an AE of IPF [10–13]. Reduced FVC patients often have decreased normal lung area due to extensive fibrosis. Patients with these characteristics are prone to developing severe lung injury that is consistent with gefitinib-associated interstitial lung disease (ILD) [14]. In the never smoking IPF patients, the baseline dyspnea grade and serial progression of dyspnea can predict the short-term development of AE [15]. Recently, Collard et al. [16] reported that baseline FVC, baseline supplemental
oxygen, baseline antacid medication, and smoking are important risk factors for AE of IPF. Thus, once we diagnose IPF, serial physiological evaluations and reducing the impairment of daily activity due to AEs are the main tasks for physicians.

3. Diagnosis Process

The International Working Group Report proposed several revised criteria for an AE of IPF in 2016 [17]. The important background for a patient is a previous diagnosis of IPF and acute worsening or development of progressive dyspnea that has a duration of less than one month. Another important change is that bronchoalveolar lavage is no longer necessarily required for the diagnosis of AE compared with the 2007 criteria [18]. Therefore, AE of IPF can be diagnosed in a general hospital. These criteria provide rather broad coverage compared to the original 2007 criteria [7,17].

The new criteria divided AE of IPF into two groups, which are, namely, triggered and idiopathic. The triggered AE consists of episodes that are related to infection, drug toxicity, and aspiration, as well as those that occur after procedures and post-operatively. In terms of history, it is important that disease duration is less than 1 month. Furthermore, we should exclude pneumothorax and pleural effusion by chest radiography, as well as pulmonary embolism by a combination of clinical history and contrast enhanced chest CT. Furthermore, if we see bilateral infiltrates on plain chest radiographs, chest CTs will be required for the evaluation of bilateral ground-glass opacity (GGO), which will be consolidated with chronic fibrotic findings such as honeycombing, traction bronchiectasis/bronchiolectasis or reticular opacity. Before arriving at a diagnosis of AE of IPF, we should exclude heart failure or volume overload clinically.

In terms of physical findings, patients invariably exhibit acute respiratory distress, with prominent use of auxiliary muscles for respiration, especially the scalene muscles of the neck. Lung auscultation reveals bilateral diffuse fine crackles. Furthermore, IPF patients sometimes have clubbed fingernails.

4. Biomarkers

In laboratory findings, classic inflammatory markers such as white blood cell counts and C-reactive protein are usually elevated [1]. In the chemistry panel, lactate dehydrogenase (LDH) is a simple and sensitive marker that predicts the short-term prognosis of AE of IPF patients. Kishaba et al. [19] reported that the serial trend of serum LDH is associated with 90-day mortality of AE. In addition, Enomoto et al. [20] showed that a serum ferritin level above 500 ng/mL predicts poor prognosis in AE of IPF. Recently, serum periostin has received attention as a potentially attractive biomarker of IPF. Serum periostin is elevated both during the acute phase and the chronic stable phase in IPF patients [21,22]. Furthermore, serum decorin is a small, leucine-rich proteoglycan that has been introduced as a novel marker for AE of IPF. Nikaido et al. [23] reported that serum decorin had a significant association with oxygenation. Further multicenter studies will be required for further validation.

Both serum KL-6 and surfactant protein-D (SP-D) are useful markers of IPF [24,25]. However, KL-6 is a high-molecular weight protein. Therefore, the response of KL-6 is slower than that of LDH, and the elevation of serum KL-6 is commonly seen after the acute phase of AE. The elevation of serum SP-D reflects inflammatory processes, so this is often elevated in patients with severe pneumonia [26]. Therefore, distinguishing AE of IPF from severe pneumonia by serum SP-D alone is relatively difficult.

5. Clinical Characteristics According to the New IPF Criteria

Based on the new 2016 proposed criteria, we reported that patients with triggered AE of IPF showed more extensive new shadow compared to those with idiopathic AE [19]. Multivariate analysis showed that the serum LDH and the serial trend of LDH predicted 90-day mortality [19]. The Kaplan–Meier survival curve of this study showed that a serum LDH level above 80 IU/L as measured within 2 weeks was associated with poor survival (p = 0.046) [19]. Yamazoe et al. [27] showed that patients with idiopathic AE were more likely to receive corticosteroids and more likely
to develop AE during the winter months. On the contrary, the triggered group was more likely to have underlying lung cancer, compared to the idiopathic group (59.1% versus 7.1%, \( p < 0.001 \)). In the idiopathic group, white blood cell and hemoglobin levels were independent predictors of in-hospital mortality [27]. Teramachi et al. [28] reported that AE of IPF accounted for approximately one-third of first hospitalizations for acute respiratory deterioration.

6. Imaging

In chest radiographs, a new bilateral diffuse shadow that is superimposed on the lower-lobe reticular shadow is the typical finding in AE of IPF patients. A comparison with previous films is a necessary first step in diagnosis.

The latest international IPF guidelines (2018) strongly insist upon the importance of chest HRCT for AE of IPF [1]. We should look for the coexistence of the usual interstitial pneumonia (UIP) pattern such as subpleural and basal predominant opacity, with peripheral dominant and heterogeneous distribution. Furthermore, there can be architectural distortion such as traction bronchiectasis and honeycombing [29]. Akira et al. [30] proposed that the CT findings of AEs of IPF should be divided into three patterns, consisting of peripheral, multifocal, and diffuse infiltrates. The prevalence of the new parenchymal shadow was significantly more frequent than the other two patterns. They also evaluated several follow up CT scans. In survivors with the peripheral pattern, the majority of GGO and consolidation regressed back to baseline levels of abnormality. In survivors with multifocal scan findings, GGO and consolidation disappeared with corticosteroid therapy. In contrast, survivors with the diffuse pattern demonstrated significant extension of GGO and consolidation. The Kaplan–Meier survival curve showed significant difference based on CT pattern [30]. In multivariate analysis, the diffuse CT pattern was the strongest predictor of mortality. In another study, Kishaba et al. [31] showed that the staging of AE of IPF is useful for the prediction of prognosis. Four important parameters were identified: serum LDH, KL-6, the ratio of partial pressure of oxygen to the fraction of inspiratory oxygen concentration, and the sum of the GGO and consolidation scores. They assigned points for each parameter and divided patients into two groups, with limited or extensive involvement. In addition, patients in the extensive group had poor prognoses compared to the limited group [31].

According to these studies, a detailed assessment of the chest HRCT findings in patients with AE of IPF can inform management and prognosis for physicians.

7. Management

The 2018 Japanese IPF treatment guidelines suggested that IPF patients with AE should be treated with corticosteroids, including pulse therapy [32]. Steroid pulse therapy is typically administered for three consecutive days. Weekly pulse therapy may sometimes be repeated once or twice. Prolonged pulse therapy may often be complicated by opportunistic infections such as pneumocystis pneumonia and viral infections. Therefore, the meticulous titration of prednisolone dosage is required during maintenance phase. Idiopathic pulmonary fibrosis itself is a fibrotic lung disease. However, there is a component of inflammation in AE of IPF [2]. Therefore, some patients respond to corticosteroids [33]. In addition, when we see a partial response with prednisolone, we commence treatment with chronic immunosuppressants, such as intravenous cyclophosphamide [34]. However, this treatment strategy is not supported by robust evidence. Recently, two novel therapies have been reported to have possible value in treating AEs of IPF. A recent report showed that direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) is an effective treatment for AE and prolongs the survival of AE of IPF patients [35–37]. PMX-DHP was originally introduced to manage sepsis or septic shock via neutrophil removal by the column. An early introduction of PMX-DHP within 3 days after disease onset was effective, especially for dermatomyositis [38]. Based on these reports, when we see severe inflammation with AE of IPF patients, we may consider PMX-DHP to be a possible therapeutic option. Recombinant human soluble thrombomodulin (rhTM), which has anti-inflammatory effects and mitigates the coagulation cascade, was also developed as a treatment for sepsis. In acute lung
injury, there is both intense procoagulant activity and severe inflammation in the lung parenchyma [39]. Therefore, the mechanism of action of rhTMs suggests that it could be a plausible therapeutic agent for AEs of IPF. Several reports have shown that intravenous administration of rhTM for six consecutive days improved the survival rate of AEs of IPF patients [40–44]. Medical insurance does not cover these two therapies for AE of IPF, so we should discuss the use of such novel treatments with patients and their families very thoroughly. Tomioka et al. [45] reported that a case of AE of IPF improved with the use of nintedanib alone. When we see mild AE of IPF patients, antifibrotic agents may play a role during acute and chronic phases. In addition, high-flow nasal cannula (HFNC) is sometimes used for IPF with reduced tachypnea and improvements in minute ventilation [46]. In AEs of IPF patients, pharmacological treatment with HFNC can provide relief of dyspnea [47]. Future multicenter studies of HFNC are eagerly anticipated.

8. Prognosis

Acute exacerbation of IPF is usually associated with a poor prognosis. Natsuizaka et al. [48] reported that AE accounts for 40% of IPF deaths. The mean survival of AE of IPF is less than one year and 90-day mortality is approximately 50%. Therefore, the prevention of AE is crucial. Recent antifibrotic agents, especially nintedanib, were shown to prevent AE of IPF in an international clinical trial [49]. The subgroup analysis showed a 75% reduction of AE with nintedanib, especially among Japanese patients [50]. Pirfenidone combined with prednisolone and rhTM may improve survival in patients with AEs of IPF [51]. Therefore, the judicious use of these antifibrotic agents is likely to provide good prognoses and prevention of AEs of IPF patients [52].

In conclusion, IPF has a heterogeneous clinical course. Based on certain risk factors, physicians should carefully monitor patient status. An adequate diagnosis of AE using clinical information and chest HRCT permits early intervention for AEs of IPF. Acute exacerbation still has poor prognosis; therefore, novel management is required.

Funding: This research received no external funding.

Conflicts of Interest: The author declare no conflict of interest.

References

1. Raghu, G.; Remy-Jardin, M.; Myers, J.L.; Richeldi, L.; Ryerson, C.J.; Lederer, D.J.; Behr, J.; Cottin, V.; Danoff, S.K.; Morell, F.; et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2018, 198, e44–e68. [CrossRef] [PubMed]
2. American Thoracic Society. European Respiratory Society Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. Am. J. Respir. Crit. Care Med 2000, 161 Pt 1, 646–664.
3. Murata, K.; Koga, Y.; Kasahara, N.; Hachisu, Y.; Nunomura, S.; Nakajima, N.; Yokoo, H.; Kaira, K.; Maeno, T.; Dobashi, K.; et al. Accumulation of periostin in acute exacerbation of familial idiopathic pulmonary fibrosis. J. Thorac. Dis. 2018, 10, E587–E591. [CrossRef] [PubMed]
4. Okamoto, T.; Mathai, S.K.; Hennessy, C.E.; Hancock, L.A.; Walts, A.D.; Stefanski, A.L.; Brown, K.K.; Lynch, D.A.; Cosgrove, G.P.; Groshong, S.D.; et al. The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2018, 315, L1–L10. [CrossRef] [PubMed]
5. Dressen, A.; Abbas, A.R.; Cabanski, C.; Reeder, J.; Ramalingam, T.R.; Neighbors, M.; Bhangale, T.R.; Brauer, M.J.; Hunkapiller, J.; Reeder, J.; et al. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: A candidate gene sequencing study. Lancet Respir. Med. 2018, 6, 603–614. [CrossRef]
6. Poletti, V.; Egan, J. Classification, natural history and staging of idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2013, 30 (Suppl. 1), 13–20. [PubMed]
7. Collard, H.R.; Moore, B.B.; Flaherty, K.R.; Brown, K.K.; Kaner, R.J.; King, T.E., Jr.; Lasky, J.A.; Loyd, J.E.; Noth, I.; Olman, M.A.; et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007, 176, 636–643. [CrossRef]
8. Saito, S.; Lasky, J.A.; Hagiwara, K.; Kondoh, Y. Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective. *Respir. Investig.* 2018, 56, 375–383. [CrossRef] [PubMed]

9. Deng, Y.; Li, Z.; Liu, J.; Wang, Z.; Cao, Y.; Mou, Y.; Fu, B.; Mo, B.; Wei, J.; Cheng, Z.; et al. Targeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis. *Hum. Mutat.* 2018, 39, 1238–1245. [CrossRef]

10. Song, J.W.; Hong, S.B.; Lim, C.M.; Koh, Y.; Kim, D.S. Acute exacerbation of idiopathic pulmonary fibrosis: Incidence, risk factors and outcome. *Eur. Respir. J.* 2011, 37, 356–363. [CrossRef] [PubMed]

11. Kondoh, Y.; Taniguchi, H.; Katsuta, T.; Kataoka, K.; Kimura, T.; Nishiyama, O.; Sakamoto, K.; Johkoh, T.; Nishimura, M.; Ono, K.; et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. *Sarcoidosis Vasc. Diffuse Lung Dis.* 2010, 27, 103–110. [PubMed]

12. Ohshima, S.; Ishikawa, N.; Horimatsu, Y.; Hattori, N.; Hirohashi, N.; Tanigawa, K.; Kohno, N.; Bonella, F.; Guzman, J.; Costabel, U. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. *Respir. Med.* 2014, 108, 1031–1039. [CrossRef] [PubMed]

13. Zubairi, A.B.S.; Ahmad, H.; Hassan, M.; Sarwar, S.; Abbas, A.; Shahzad, T.; Irfan, M. Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: An experience from a tertiary care center in Pakistan. *Clin. Respir. J.* 2018, 12, 1191–1196. [CrossRef] [PubMed]

14. Shah, R.R. Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges and Therapeutic Dilemmas. *Drug. Saf.* 2016, 39, 1073–1091. [CrossRef]

15. Kishaba, T.; Nagano, H.; Nei, Y.; Yamashiro, S. Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. *J. Thorac. Dis.* 2016, 8, 1112–1120. [CrossRef] [PubMed]

16. Collard, H.R.; Richeldi, L.; Kim, D.S.; Taniguchi, H.; Tschoepe, I.; Luisetti, M.; Roman, J.; Tino, G.; Schlenker-Herceg, R.; Hallmann, C.; et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2017, 49, 1601339. [CrossRef] [PubMed]

17. Collard, H.R.; Ryerson, C.J.; Corte, T.J.; Jenkins, G.; Kondoh, Y.; Lederer, D.J.; Lee, J.S.; Maher, T.M.; Wells, A.Y.; Antoniou, K.M.; et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *Am. J. Respir. Crit. Care Med.* 2016, 194, 265–275. [CrossRef]

18. Kishaba, T. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. *Eurasian J. Med.* 2017, 49, 204–206. [CrossRef]

19. Kishaba, T.; Nei, Y.; Momose, M.; Nagano, H.; Yamashiro, S. Clinical Characteristics Based on the New Criteria of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis. *Eurasian J. Med.* 2018, 50, 6–10. [CrossRef]

20. Enomoto, N.; Oyama, Y.; Enomoto, Y.; Mikamo, M.; Karayama, M.; Hozumi, H.; Suzuki, Y.; Kono, M.; Furuhashi, K.; Fujisawa, T.; et al. Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis. *Clin. Respir. J.* 2018, 12, 2378–2389. [CrossRef]

21. Tajiri, M.; Okamoto, M.; Fujimoto, K.; Johkoh, T.; Ono, J.; Tominaga, M.; Azuma, K.; Kawayama, T.; Ohta, S.; Izuhara, K.; et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. *Respir. Investig.* 2015, 53, 73–81. [CrossRef] [PubMed]

22. Ohta, S.; Okamoto, M.; Fujimoto, K.; Sakamoto, N.; Takahashi, K.; Yamamoto, H.; Kushima, H.; Ishii, H.; Akasaka, K.; Ono, J.; et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. *PLoS ONE* 2017, 12, e0174547. [CrossRef]

23. Nikaido, T.; Tanino, Y.; Wang, X.; Sato, Y.; Togawa, R.; Kituchi, M.; Misa, K.; Saito, K.; Fukuura, N.; Kawamata, T.; et al. Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis. *J. Thorac. Dis.* 2018, 10, 5346–5358. [PubMed]

24. Ishikawa, N.; Hattori, N.; Yokoyama, A.; Kohno, N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. *Respir. Investig.* 2012, 50, 3–13. [CrossRef] [PubMed]

25. Chiba, H.; Otsuka, M.; Takahashi, H. Significance of molecular biomarkers in idiopathic pulmonary fibrosis: A mini review. *Respir. Investig.* 2018, 56, 384–391. [CrossRef] [PubMed]

26. Murata, M.; Otsuka, M.; Ashida, N.; Yamada, G.; Kuronuma, K.; Chiba, H.; Takahashi, H. Surfactant protein D is a useful biomarker for monitoring acute lung injury in rats. *Exp. Lung Res.* 2016, 42, 314–321. [CrossRef]

27. Yamazoe, M.; Tomioka, H. Acute exacerbation of idiopathic pulmonary fibrosis: A 10-year single-centre retrospective study. *BMJ Open Respir. Res.* 2018, 5, e000342. [CrossRef]
28. Teramachi, R.; Kondoh, Y.; Kataoka, K.; Taniguchi, H.; Matsuda, T.; Kimura, T.; Yokoyama, T.; Yamano, Y.; Furukawa, T.; Sakamoto, K.; et al. Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis. Respir. Med. 2018, 143, 147–152. [CrossRef]

29. Raaghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.F.; Flaherty, K.R.; Lasky, J.A.; et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011, 183, 788–824. [CrossRef]

30. Akira, M.; Kozuka, T.; Yamamoto, S.; Sakatani, M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008, 178, 372–378. [CrossRef]

31. Kishaba, T.; Tamaki, H.; Shimaoka, Y.; Fukuyama, H.; Yamashiro, S. Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis. Lung 2014, 192, 141–149. [CrossRef] [PubMed]

32. Homma, S.; Bando, M.; Azuma, A.; Sakamoto, S.; Sugino, K.; Ishii, Y.; Izumi, S.; Inase, N.; Inoue, Y.; Ebina, M.; et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir. Investig. 2018, 56, 268–291. [CrossRef] [PubMed]

33. Arai, T.; Tachibana, K.; Sugimoto, C.; Inoue, Y.; Tokura, S.; Okuma, T.; Akira, M.; Kitaichi, M.; Hayashi, S.; Inoue, Y. High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirpiology 2017, 22, 1363–1370. [CrossRef] [PubMed]

34. Novelli, L.; Ruggiero, R.; De Giacomi, F.; Biffi, A.; Faverio, P.; Bilucaglia, L.; Gerber, S.; Messinesi, G.; Pesci, A. Corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A single center experience and literature review. Sarcoidosis Vasc. Diffuse Lung Dis. 2016, 33, 385–391. [PubMed]

35. Enomoto, N.; Suda, T.; Uto, T.; Kato, M.; Kaida, Y.; Ozawa, Y.; Miyazaki, H.; Kuroishi, S.; Hashimoto, D.; Naito, T.; et al. Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology 2008, 13, 452–460. [CrossRef] [PubMed]

36. Tachibana, K.; Inoue, Y.; Nishiyama, A.; Sugimoto, C.; Matsumuro, A.; Hirose, M.; Kitaichi, M.; Akira, M.; Arai, T.; Hayashi, S.; et al. Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: Serum IL-7 as a prognostic marker. Sarcoidosis Vasc. Diffuse Lung Dis. 2011, 28, 113–122. [PubMed]

37. Enomoto, N.; Mikamo, M.; Oyama, Y.; Kono, M.; Hashimoto, D.; Fujisawa, T.; Inui, N.; Nakamura, Y.; Yasuda, H.; Kato, A.; et al. Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulm. Med. 2015, 15, 15. [CrossRef] [PubMed]

38. Takada, T.; Asakawa, K.; Sakagami, T.; Moriyama, H.; Kazama, J.; Suzuki, E.; Narita, I. Effects of direct hemoperfusion with polymyxin B-immobilized fiber on rapidly progressive interstitial lung diseases. Intern. Med. 2014, 53, 1921–1926. [CrossRef] [PubMed]

39. Suzuki, A.; Taniguchi, H.; Kondoh, Y.; Ando, M.; Watanabe, N.; Kimura, T.; Kataoka, K.; Yokoyama, T.; Sakamoto, K.; Hasegawa, Y. Soluble thrombomodulin in bronchoalveolar lavage fluid is an independent predictor of severe drug-induced lung injury. Respirpiology 2017, 22, 744–749. [CrossRef] [PubMed]

40. Tsushima, K.; Yamaguchi, K.; Kono, Y.; Yokoyama, T.; Kubo, K.; Matsumura, T.; Ichimura, Y.; Abe, M.; Terada, J.; Tsumi, K. Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: A proof of concept study. Pulm. Pharmacol. Ther. 2014, 29, 233–240. [CrossRef] [PubMed]

41. Ishii, T.; Sakamoto; S.; Kinoshita, A.; Sugino, K.; Kurokasi, A.; Homma, S. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study. Respiration 2015, 89, 201–207. [CrossRef]

42. Kataoka, K.; Taniguchi, H.; Kondoh, Y.; Nishiyama, O.; Kimura, T.; Matsuda, T.; Yokoyama, T.; Sakamoto, K.; Ando, M. Recombinant Human Thrombomodulin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Chest 2015, 148, 436–443. [CrossRef]

43. Hayakawa, S.; Matusuzawa, Y.; Irie, T.; Rikitake, H.; Okada, N.; Suzuki, Y. Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: A single arm, non-randomized prospective clinical trial. Multidisip. Respir. Med. 2016, 11, 38. [CrossRef] [PubMed]

44. Sakamoto, S.; Shimizu, H.; Isshiki, T.; Sugino, K.; Kurosaki, A.; Homma, S. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: A historically controlled study. Respir. Investig. 2018, 56, 136–143. [CrossRef] [PubMed]
45. Tomioka, H.; Takada, H. Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis. 
Respirol. Case Rep. 2017, 5, e00215. [CrossRef]

46. Bräunlich, J.; Beyer, D.; Mai, D.; Hammerschmidt, S.; Seyfarth, H.J.; Wirtz, H. Effects of nasal high flow on 
ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration 2013, 85, 319–325. 
[CrossRef] [PubMed]

47. Millan-Billi, P.; Serra, C.; Alonso Leon, A.; Castillo, D. Comorbidities, Complications and Non-Pharmacologic 
Treatment in Idiopathic Pulmonary Fibrosis. Med. Sci. 2018, 6, 59. [CrossRef] [PubMed]

48. Natsuizaka, M.; Chiba, H.; Kuronuma, K.; Otsuka, M.; Kudo, K.; Mori, M.; Bando, M.; Sugiyama, Y.; 
Takahashi, H. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and 
investigation of ethnic differences. Am. J. Respir. Crit. Care Med. 2014, 190, 773–779. [CrossRef]

49. Richeldi, L.; Cottin, V.; du Bois, R.M.; Selman, M.; Kimura, T.; Bailes, Z.; Schlenker-Herceg, R.; Stowasser, S.; 
Brown, K.K. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the 
TOMORROW and INPULSIS® trials. Respir. Med. 2016, 113, 74–79. [CrossRef] [PubMed]

50. Azuma, A.; Taniguchi, H.; Inoue, Y.; Kondoh, Y.; Ogura, T.; Homma, S.; Fujimoto, T.; Sakamoto, W.; 
Sugiyama, Y.; Nukiwa, T. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup 
analysis of the INPULSIS® randomized trials. Respirology 2017, 22, 750–757. [CrossRef] [PubMed]

51. Furuya, K.; Sakamoto, S.; Shimizu, H.; Sekiya, M.; Kinoshita, A.; Isshiki, T.; Sugino, K.; Matsumoto, K.; 
Homma, S. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study. 
Respir. Med. 2017, 126, 93–99. [CrossRef] [PubMed]

52. Lederer, D.J.; Martinez, F.J. Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 2018, 379, 797–798. [CrossRef] 
[PubMed]

© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).